Category Archives: Business and Investments

Latest From Business and Investments

The New Demand for Biotech Industry Talent

scientists115x76

Biotechnology is a multi-disciplinary field involving the integration of knowledge and skills drawn from numerous disciplines, such as microbiology, biochemistry, genetics, molecular biology and chemistry. Traditionally, the field of biotechnology has required a workforce with a wide array of highly specialized skills and training. Interestingly though, a shift has begun to take place, favoring people with interdisciplinary academic training who can support more than one project team and work across multiple areas. On September 10, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: ,

JOBS Act Deconstructed: Regulation D

150639480

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act.  BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage.  Since the JOBS Act passed, attention has focused mostly on the law’s effects on the IPO market.  This is largely because the IPO On-Ramp was the Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

JOBS Act: Rule 506 Goes Into Effect Today

DC in Fall

Since Congress passed the Jumpstart our Business Startups (JOBS) Act last spring, there have been 39 IPOs in the biotech industry – and counting!  Today, another provision from the JOBS Act takes effect that will further enhance biotech capital formation. Pursuant to rules mandated by the JOBS Act, companies are now able to use general solicitation to advertise to investors when conducting an offering under Rule 506 of SEC Regulation D.  Rule 506 is a Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: ,

BIO Investor Forum Company Snapshot: Opsona Therapeutics

opsona115x76

Opsona Therapeutics will be participating in the upcoming BIO Investor Forum, and will be giving a presentation on their work in the autoimmune/inflammatory diseases and oncology space (among other indications). To learn more about their company, please read one of our final company snapshots below. Company Snapshot What is your company’s lead product or technology? Opsona’s lead product OPN-305 is a fully humanized monoclonal IgG4 antibody targeting Toll-like-receptor-2 (TLR2), which is in clinical development as Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BioCentury This Week: Death & Taxes – Startups Need Fixes

BioCenturyTV

Vitae CEO Jeff Hatfield, Ernst & Young Partner Christopher Ohmes, and GPB Scientific CEO Michael Grisham will be discussing proposed tax changes that could spur billions of dollars in investment and create hundreds of thousands of jobs on BioCentury This Week airing Sunday September, 15 at 8:30am EST on WUSA-9. Biotech startups face death before taxes and unless investors are willing to finance years of losses, technologies that could save and improve lives are left Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,